Speaking at the American Society of Retina Specialists 2021 annual meeting, Richard B. Rosen, MD, DSc (Hon) noted that clinical OCT and offers a new clinical biomarker for tracking the onset and progression of retinal vascular disease and the response to therapy.
Justis P. Ehlers, MD, discusses the findings from a higher-order OCT analysis for inflammatory signal biomarkers in the HAWK Study.
During a presentation at American Society of Retina Specialists 2021 annual meeting in San Antonio, Sunir Garg, MD, presented data showing that universal masking does not seem to increase the risk of developing endophthalmitis, and it may cause a reduction in culture positive endophthalmitis.
During a presentation at the American Society of Retina Specialists 2021 annual meeting in San Antonio, Texas, Yoshihiro Yonekawa, MD, warned of the potential risk of endophthalmitis with the use of implantable MIGS devices.
Speaking at the American Society of Retina Specialists 2021 annual meeting in San Antonio, Rishi P. Singh, MD, provided results of the VISTA and VIVID studies, and he pointed out that the findings could help physicians set expectations of DME therapy.
Caroline Baumal, MD, provides an overview of the efficacy, safety and durability of faricimab in diabetic macular edema (DME) at ASRS 2021.
During a presentation at the American Society of Retina Specialists 2021 annual meeting in San Antonio, W. Lloyd Clark, MD, presented results of the PANORAMA Study. The focus of the study, Clark said, was to identify the factors that increase the risk of complications in patients with nonproliferative diabetic retinopathy to provide information for making decisions on treatment choices.
Results from our recent poll about ASRS 2021 meeting attendance shows that ophthalmologists are ready to participate in events, both in-person and online.
American Society of Retina Specialists (ASRS) meeting offers scientific sessions, symposia, discussion groups, opportunities for attendees.
The American Society of Retina Specialists is gearing up for its 39th annual scientific meeting Oct. 8-12 at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.
Understanding the per-person cost differences with 3 key management strategies for a better-informed treatment selection
How this method of anesthesia may provide benefits to both the patient and physician
Following trends by geographic variation in practice patterns, perceptions toward opioids, and patient population
Visual acuity outcomes at 6 months’ post-treatment were similar, regardless of the use of anti-VEGF therapy.
Modifier-25 same-day examinations are critical to the successful treatment and overall health and well being of these patients.
Measuring high-quality care cannot be a barrier to providing it, notes John T. Thompson, MD.
Results could provide a new preferred treatment paradigm for this population
S.K. Steven Houston III, MD, shares how his practice has put to use recent retina innovations and adapted to accommodate the ever-changing operating room spacing and set-up in the current COVID-19 environment.
The application of sub-silicone oil TA crystals over relaxing retinectomy sites is a viable option in patients with complex RD with extreme PVR.
Retina specialists Caesar Luo, MD, of Bay Area Retina Associates, and S.K. Steven Houston III, MD, of Florida Retina Institute, share their outlooks on retina innovation in the "year of the eye" amid a global pandemic.
Dilraj Grewal, MD, speaks on his presentation "Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert," during ASRS 2020.
Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."
Daniel F. Kiernan, MD, FACS, speaks on the key findings and take-aways of his presentation "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery."
S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment
Caesar Luo, MD, shares the take-away points from his ASRS presentation, and how the topics from his talk may be applied day to day in retinal practice.
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.
Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD.
Dilraj Grewal, MD, associate professor of ophthalmology at Duke Eye Center/ director of grading at the Duke Reading Center, speaks on his presentation "Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert," during the virtual 2020 ASRS meeting.
ASRS 2020: Josh Anderson speaks on the highlights from Alcon, including new data on the performance benefits of the Hypervit dual blade 20,000 cpm probe and the launch of the NGENUITY 1.4 upgrade.
PDS with ranibizumab is proving to be an innovation solution for nAMD patients. Peter Campochiaro, MD, detailed findings of phase 2 of the Ladder Trial and ongoing Archway Trial during the virtual 2020 ASRS annual meeting.
